MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020
Two of the abstracts accepted for presentation focus on echocardiographic and cardiac magnetic resonance imaging (CMR) data from the pivotal EXPLORER-HCM clinical trial of mavacamten. These data are expected to build on the previously published safety and efficacy results from the Phase 3 clinical study by providing additional insights into changes in cardiac structure and function.
Featured Science Session:
- Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR substudy (
Session: High Profile Clinical Science in CVD
Sara Saberi, M.D., University of Michigan
Available as of
ePosters on Demand
- Mavacamten Favorably Impacts Key Pathophysiologic Processes in Obstructive Hypertrophic Cardiomyopathy: Results From the EXPLORER-HCM Study (#P1732)
Session: Different Aspects of Hypertrophic Cardiomyopathy
Paul Dudley WhiteAward recipient
Sheila Hegde, M.D., Brigham and Women’s Hospital
- Accelerometer-measured Activity in Non-obstructive Hypertrophic Cardiomyopathy: Patient-generated Activity Measures Correlate With, and are Convolutional Neural Network Predictors of, Clinical Parameters in the MAVERICK-HCM Study (P2047)
Session: Evaluation of Cardiac Amyloidosis and Hypertrophic Cardiomyopathy
Euan Ashley, M.D., Stanford University Medicine
- Chronic Treatment With A Mavacamten-like Myosin-modulator (MYK-581) Prevents Left-atrial Remodeling, Decreases Cardiac Troponin Leakage, And Blunts Mortality In A Mini-pig Model Of Inherited Hypertrophic Cardiomyopathy (P2394)
Session: Insights from HF Clinical Tirals and Emerging Pharmacological Therapies for Heart Failure
Carlos del Rio, PhD, FACC, MyoKardia
ePosters on Demand: SHaRe research
- Primary Prevention Implantable Cardioverter Defibrillator Utilization for Hypertrophic Cardiomyopathy in US vs Non-US: Findings from the Share Registry (P1599)
Session: Advances in Cardiac Implantable Device Therapy
Victor Nauffal, M.D., Brigham and Women’s Hospital
- The Natural History of Asymptomatic and Mildly Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the Share Registry (P2380)
Session: Cardiomyopathies, arrhythmias Genomics and Mechanisms
Monica Ahluwalia, M.D., Brigham and Women’s Hospital
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease, 2) targeting the proteins that modulate a given condition, 3) identifying patient populations with shared disease characteristics and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
Michelle CorralExecutive Director, Corporate Communications and Investor Relations MyoKardia, Inc.650-351-4690 email@example.com Hannah Deresiewicz(investors) Stern Investor Relations, Inc. 212-362-1200 firstname.lastname@example.org Julie Normant(media) W2O 628-213-3754 email@example.com
Source: MyoKardia, Inc.